<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Acharya, Sundaram</style></author><author><style face="normal" font="default" size="100%">Mishra, Arpit</style></author><author><style face="normal" font="default" size="100%">Paul, Deepanjan</style></author><author><style face="normal" font="default" size="100%">Ansari, Asgar Hussain</style></author><author><style face="normal" font="default" size="100%">Azhar, Mohd</style></author><author><style face="normal" font="default" size="100%">Kumar, Manoj</style></author><author><style face="normal" font="default" size="100%">Rauthan, Riya</style></author><author><style face="normal" font="default" size="100%">Sharma, Namrata</style></author><author><style face="normal" font="default" size="100%">Aich, Meghali</style></author><author><style face="normal" font="default" size="100%">Sinha, Dipanjali</style></author><author><style face="normal" font="default" size="100%">Sharma, Saumya</style></author><author><style face="normal" font="default" size="100%">Jain, Shivani</style></author><author><style face="normal" font="default" size="100%">Ray, Arjun</style></author><author><style face="normal" font="default" size="100%">Jain, Suman</style></author><author><style face="normal" font="default" size="100%">Ramalingam, Sivaprakash</style></author><author><style face="normal" font="default" size="100%">Maiti, Souvik</style></author><author><style face="normal" font="default" size="100%">Chakraborty, Debojyoti</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Francisella novicida Cas9 interrogates genomic DNA with very high specificity and can be used for mammalian genome editing</style></title><secondary-title><style face="normal" font="default" size="100%">Proceedings of the National Academy of Sciences of the United States of America</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">CRISPR Cas9</style></keyword><keyword><style  face="normal" font="default" size="100%">gene therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Genome editing</style></keyword><keyword><style  face="normal" font="default" size="100%">iPSCs</style></keyword><keyword><style  face="normal" font="default" size="100%">sickle cell anemia</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">OCT</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">116</style></volume><pages><style face="normal" font="default" size="100%">20959-20968</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Genome editing using the CRISPR/Cas9 system has been used to make precise heritable changes in the DNA of organisms. Although the widely used Streptococcus pyogenes Cas9 (SpCas9) and its engineered variants have been efficiently harnessed for numerous gene-editing applications across different platforms, concerns remain regarding their putative off-targeting at multiple loci across the genome. Here we report that Francisella novicida Cas9 (FnCas9) shows a very high specificity of binding to its intended targets and negligible binding to off-target loci. The specificity is determined by its minimal binding affinity with DNA when mismatches to the target single-guide RNA (sgRNA) are present in the sgRNA:DNA heteroduplex. FnCas9 produces staggered cleavage, higher homology-directed repair rates, and very low nonspecific genome editing compared to SpCas9. We demonstrate FnCas9-mediated correction of the sickle cell mutation in patient-derived induced pluripotent stem cells and propose that it can be used for precise therapeutic genome editing for a wide variety of genetic disorders.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">42</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;9.580&lt;/p&gt;
</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kalshetti, Rupali G.</style></author><author><style face="normal" font="default" size="100%">Rajput, Raveena</style></author><author><style face="normal" font="default" size="100%">Motiwala, Zenia</style></author><author><style face="normal" font="default" size="100%">Reddy, D. Srinivasa</style></author><author><style face="normal" font="default" size="100%">Kulkarni, Kiran A.</style></author><author><style face="normal" font="default" size="100%">V. Ramana, Chepuri</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Postmodification of voxelotor (GBT 440) via [Rh]-catalyzed cross dehydrogenative coupling with olefins br</style></title><secondary-title><style face="normal" font="default" size="100%">Bioorganic &amp; Medicinal Chemistry Letters</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">CDC Coupling</style></keyword><keyword><style  face="normal" font="default" size="100%">GBT-440 (Voxelotor)</style></keyword><keyword><style  face="normal" font="default" size="100%">Rh(III) catalysis</style></keyword><keyword><style  face="normal" font="default" size="100%">sickle cell anemia</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">DEC</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">77</style></volume><pages><style face="normal" font="default" size="100%">129022</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;
	The directed Rh(III)-catalyzed cross dehydrogenative coupling of the pyrazole unit of the GBT-440 scaffold has been explored with simple as well as conjugated olefins to synthesize post-functionalized GBT-440 analogues. The screening of these synthesized compounds for improving the oxygen binding efficiency of the hemoglobin isolated from the sickled red blood cells revealed that some of these compounds are as good as GBT-440.&lt;/p&gt;
</style></abstract><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;
	Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;
	2.940&lt;/p&gt;
</style></custom4></record></records></xml>